Anzeige
Mehr »
Donnerstag, 07.08.2025 - Börsentäglich über 12.000 News
Große CEO-Enthüllung: Analysten sehen +56% Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DZJ0 | ISIN: US44148G2049 | Ticker-Symbol:
NASDAQ
06.08.25 | 21:56
1,310 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HOTH THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
HOTH THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur HOTH THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiHoth Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
HOTH THERAPEUTICS Aktie jetzt für 0€ handeln
30.07.Hoth Therapeutics Engages ICON to Expand Clinical Trial for HT-0017
29.07.Hoth Therapeutics, Inc.: Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe137The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 /PRNewswire/...
► Artikel lesen
22.07.Hoth Therapeutics partners with VA to test GDNF therapy for obesity2
25.06.Silo Pharma, Hoth Therapeutics Enter LOI to Develop Obesity Treatment1
25.06.Hoth Therapeutics, Inc: Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market328NEW YORK, June 25, 2025 - (ACN Newswire) - Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery...
► Artikel lesen
25.06.Silo Pharma to form JV with Hoth Therapeutics for obesity treatment1
25.06.Silo Pharma and Hoth Therapeutics plan joint venture for obesity treatment2
25.06.Hoth Therapeutics, Silo Pharma Launch JV To Commercialize VA-Invented Obesity Drug-
25.06.Hoth und Silo gründen Joint Venture für VA-lizenzierte Adipositas-Behandlung1
25.06.Silo Pharma, Inc.: Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market158Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental...
► Artikel lesen
24.06.Hoth Therapeutics' Topical Gel Shows Promise In Mitigating Cancer Treatment Related Skin Problems1
24.06.Hoth Therapeutics stock rises after positive Phase 2a trial results7
24.06.Hoth Therapeutics, Inc.: Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects105Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities. Hoth...
► Artikel lesen
20.06.Hoth Therapeutics, Inc. - 8-K, Current Report2
18.06.Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid1
18.06.Hoth Therapeutics, Inc.: Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth148NEW YORK, June 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies...
► Artikel lesen
18.06.Hoth Therapeutics reports positive preclinical safety data for HT-KIT3
18.06.Hoth Therapeutics, Inc.: Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway124HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT - Dose-Dependent Activity, No Toxicity, IND on Deck HOTH announces strong preclinical...
► Artikel lesen
11.06.Hoth Therapeutics plans expanded access program for cancer skin toxicity drug5
Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1